Last reviewed 2026-04-19 · How we verify

ABAGOVOMAB

Abagovomab is a vaccine that helps the immune system fight ovarian cancer by targeting tumor cells.

Abagovomab is a monoclonal antibody vaccine designed for immunotherapy in ovarian cancer. It stimulates the immune system to target tumor cells. Its key differentiator is its use in active immunotherapy to prolong remission in ovarian cancer patients.

At a glance

Mechanism of action

Abagovomab is a type of cancer treatment that works by helping the body's immune system recognize and attack cancer cells. It is given as a vaccine, which means it trains the immune system to identify specific markers on cancer cells so it can destroy them more effectively. This approach is different from traditional chemotherapy because it aims to boost the body's natural defenses rather than directly killing cancer cells with drugs.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Phase I/II Trial of ACA 125 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer (Phase 1)
• Phase I Trial of the Monoclonal Anti-Idiotype Antibody ACA125 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (Phase 1)
• A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy (Phase 2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ABAGOVOMAB CI brief — competitive landscape report
• ABAGOVOMAB updates RSS · CI watch RSS
• portfolio CI